NEO

Neogenomics Stock Analysis

AI Rating

Neutral
  • Quality5/10
  • Growth↓ 0/10
  • Momentum↑ 6/10
Neogenomics sales and earnings growth
NEO Growth
Low
  • Revenue Y/Y↑ 10.11%
  • EPS Y/Y↓ -35.48%
  • FCF Y/Y↑ 36.02%
Neogenomics gross and profit margin trends
NEO Profitability
Neutral
  • Gross margin ↑ 43.20%
  • EPS margin↓ -14.90%
  • ROIC↓ -14.90%
Neogenomics net debt vs free cash flow
NEO Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↑ 11.5
  • Interest coverage↓ -28.4

Neogenomics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Diagnostics & Research stocks ↗